Azithromycin for treatment of bronchiolitis obliterans syndrome in adult lung transplant recipients
References
Additional references
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD.[Erratum appears in N Engl J Med. 2012 Apr 5;366(14):1356]. New England Journal of Medicine 2011;365(8):689‐98. [MEDLINE: 21864166]
Albert RK, Schuller JL, COPD Clinical Research Network. Macrolide antibiotics and the risk of cardiac arrhythmias. American Journal of Respiratory & Critical Care Medicine 2014;189(10):1173‐80. [MEDLINE: 24707986]
Brusselle GG, Vanderstichele C, Jordan P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double‐blind placebo‐controlled trial. Thorax 2013;68(4):322‐9. [MEDLINE: 23291349]
Corris PA, Ryan VA, Small T, Lordan J, Fisher AJ, Meachery G, et al. A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax 2015;70(5):442‐50. [MEDLINE: 25714615]
Diamond DA, Michalski JM, Lynch JP, Trulock EP. Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. International Journal of Radiation Oncology, Biology, Physics 1998;41(4):795‐800. [MEDLINE: 9652840]
Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. Journal of Heart & Lung Transplantation 2002;21(3):297‐310. [MEDLINE: 11897515]
Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. American Journal of Transplantation 2005;5(3):537‐43. [MEDLINE: 15707408]
Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. American Journal of Respiratory and Critical Care Medicine 2003;168(1):121‐5. [MEDLINE: 12672648]
Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long‐term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008;85(1):36‐41. [MEDLINE: 18192909]
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [MEDLINE: 18436948]
Hansen CR, Pressler T, Hoiby N, Johansen HK. Long‐term, low‐dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. Journal of Cystic Fibrosis 2009;8(1):58‐62. [MEDLINE: 18849202]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [PUBMED: 12958120]
Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hui D, Yan F, Chen RH. The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases. Journal of Thoracic Disease 2013;5(6):613‐7. [MEDLINE: 24255774]
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, et al. The registry of the International Society for Heart and Lung Transplantation: thirty‐first adult lung and heart‐lung transplant report‐‐2014; focus theme: retransplantation. Journal of Heart & Lung Transplantation 2014;33(10):1009‐24. [MEDLINE: 25242125]
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty‐second Official Adult Lung and Heart‐Lung Transplantation Report—2015; Focus Theme: Early Graft Failure. Journal of Heart & Lung Transplantation 2015;34(10):1264‐77. [MEDLINE: 26454740]
Jain R, Hachem RR, Morrell MR, Trulock EP, Chakinala MM, Yusen RD, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. Journal of Heart & Lung Transplantation 2010;29(5):531‐7. [MEDLINE: 20133163]
Kapila A, Baz MA, Valentine VG, Bhorade SM, AIRSAC investigators. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey. Journal of Heart & Lung Transplantation 2015;34(1):65‐74. [MEDLINE: 25447585]
McKay C, Knight KA, Wright C. Beyond cancer treatment ‐ a review of total lymphoid irradiation for heart and lung transplant recipients. Journal of Medical Radiation Sciences 2014;61(3):202‐9. [MEDLINE: 26229656]
Mertens V, Blondeau K, Pauwels A, Farre R, Vanaudenaerde B, Vos R, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Digestive Diseases & Sciences 2009;54(5):972‐9. [MEDLINE: 19241165]
Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. European Respiratory Journal 2014;44(6):1479‐503. [MEDLINE: 25359357]
Mick P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug reaction associated with low‐dose oral azithromycin. Journal of Otolaryngology 2007;36(5):257‐63. [MEDLINE: 17963663]
Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory & Critical Care Medicine 2013;187(7):680‐9. [MEDLINE: 23540878]
Pomares X, Monton C, Espata M, Casabon J, Monso E, Gallego M. Long‐term azithromycin therapy in patients with severe COPD and repeated exacerbations. International Journal of COPD 2011;6:449‐56. [MEDLINE: 22003290]
Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z. Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients. Canadian Respiratory Journal 2008;15(4):199‐202. [MEDLINE: 18551201]
Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. New England Journal of Medicine 2012;366(20):1881‐90. [MEDLINE: 22591294]
Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Schünemann HJ, Oxman AD, Higgins JP, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long‐term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. Journal of Heart & Lung Transplantation 2005;24(9):1440‐3. [MEDLINE: 16143268]
Vanaudenaerd BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. European Respiratory Journal 2008;32(4):832‐43. [MEDLINE: 18827151]
Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004;77(9):1465‐7. [MEDLINE: 15167610]
Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin‐8 in patients with bronchiolitis obliterans syndrome. American Journal of Respiratory & Critical Care Medicine 2006;174(5):566‐70. [MEDLINE: 16741151]
Verleden GM, Lievens Y, Dupont LJ, Van Raemdonck DE, De Vleeschauwer SI, Vos R, et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplantation Proceedings 2009;41(5):1816‐20. [MEDLINE: 19545735]
Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. Journal of Heart & Lung Transplantation 2014;33(2):127‐33. [MEDLINE: 24374027]
Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems‐Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. European Respiratory Journal 2011;37(1):164‐72. [MEDLINE: 20562124]
Vos R, Vanaudenaerde BM, Verleden SE, Ruttens D, Vaneylen A, Van Raemdonck DE, et al. Anti‐inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation 2012;94(2):101‐9. [MEDLINE: 22461039]
Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. American Journal of Respiratory & Critical Care Medicine 2005;172(6):772‐5. [MEDLINE: 15976371]
